Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure.
Journal of critical care(2023)
摘要
Compared to low dose tocilizumab, the high dose did not provide additional efficacy and mortality benefit but resulted in higher fungal and viral infections. This study illustrates that low dose tocilizumab can be an alternative to high dose during a drug shortage of tocilizumab without compensating for efficacy and safety, conserving resources for more patients.
更多查看译文
关键词
Corticosteroids,Immunosuppression,Interleukins,Medication therapy management,Respiratory failure,Respiratory infections
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要